Israeli Oral Vaccine against COVID received permission to test in South Africa. This announced a developer company – ORAVAX MEDICAL. South African regulator allowed the company to start a set of volunteers for the first phase of the clinical testing of the new vaccine from COVID-19. Its feature is that the drug is not introduced in injections, but orally – in tablets or capsules, reports The Jerusalem Post.
ORAVAX Medical is the “daughter” Oramed Pharmaceuticals – Israeli company with headquarters in Jerusalem.
“Oral oravax candidate vaccine can offer an effective potential solution for fighting a pandemic, be it a revaccination or vaccination of unvaccasted,” said the general director of the company Nadav Kidron.
According to him, the oral vaccine will be easier to use – it will be possible to independently take at home. This will facilitate the rapid and large-scale deployment of vaccine campaigns, writes the “Details” edition,
According to Kidron, the ORAVAX candidate vaccine is aimed at three proteins in the coronavirus structure, unlike the moderna and pfizer vaccinations, which are “introducing” an immune system with a spike protein. This allows you to hope that the Israeli vaccine will maintain its effectiveness and against new coronavirus mutations.
It is noted that the first phase of clinical trials, which will begin in South Africa, is only the beginning of a long process. In its course, the vaccine will be experienced by dozens of healthy adult volunteers to test its safety, tolerability and other characteristics.
After the first, the campaign plans to deploy the second and third phases of tests when the efficiency of the vaccine is checked on hundreds and thousands of volunteers.